Cancer-Associated Fibroblasts in radiotherapy: bystanders or protagonists?
Inigo Martinez-Zubiaurre,
Norway
MO-0143
Abstract
Cancer-Associated Fibroblasts in radiotherapy: bystanders or protagonists?
Authors: Inigo Martinez-Zubiaurre1, Turid Hellevik2, Rodrigo Berzaghi3, Kristin Lode3, Nannan Yang4
1UiT the Arctic University of Norway, Clinical Medicine, Tromsø, Norway; 2University Hospital of Northern Norway, Radiation Oncology, Tromsø, Norway; 3UiT The Arctic University of Norway, Clinical Medicine, Tromsø, Norway; 4UiT The Arctic University of Norway, Community Medicine, Tromsø, Norway
Show Affiliations
Hide Affiliations
Purpose or Objective
Cancer-associated fibroblasts (CAFs)
represent a heterogeneous population of connective tissue cells that are both
numerically and functionally prominent constituents of solid neoplasms. The
role that CAFs play on tumor responses to radiotherapy is largely unknown. This study
was undertaken to explore potential changes in the protumorigenic and
immunosuppressive functions of CAFs in the context of radiotherapy.
Material and Methods
In vitro experiments were performed using
human CAFs isolated from fresh non-small cell lung carcinoma tumor tissues.
Radiation-induced phenotypic and epigenetic changes in CAFs were studied Tumor
regulatory functions of irradiated (iCAFs) and control CAFs was compared in
co-culture systems with different lung tumor cell lines. Pro-tumorigenic and
radioprotective effects of iCAFs were studied using proliferation, migration
and clonogenic assays. Induction of EMT in tumor cells by iCAFs was also
explored. Radiation-induced CAFs changes and tumor growth regulation was also
studied in in vivo models.
Results
Our data show a
dose-dependent induction of cell senescence in CAFs, with a concomitant
reduction of the proliferative and migratory capacity. Expression of CAF
specific markers FAP-1, FSP-1, PDGFRa/b and α-SMA remained
unchanged following exposure to ionizing radiation (IR), whereas expression of
podoplanin was reduced. The proliferative and migratory rate of tumor cells
remained unchanged upon co-culturing with irradiated or control CAFs, and
clonogenic survival of tumor cells was also unaffected. However, CAF-mediated
EMT effects on tumor cells was reduced upon radiation. Preliminary in vivo
observations indicate that ionizing radiation does not alter the amount or the
expression of CAF activation markers in tumors. We are presently exploring the
contribution of CAFs on radiotherapy responses by means of CAF-depletion and
CAF-overexpression in in vivo models.
Conclusion
IR delivered at clinically relevant doses induces
important phenotypic changes in CAFs but does not appear to alter substantially
CAF-mediated pro-tumorigenic or radioprotective functions in tumor cells. CAF
abundance and cell signature markers remain unchanged upon external beam
radiotherapy of subcutaneously grown tumors. The ultimate role of CAFs on tumor
responses to radiotherapy warrant further investigations.